This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Phaeochromocytoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Phaeochromocytomas are functional tumours that arise from chromaffin cells in the adrenal medulla.

  • incidence among the general population is about 0.8 per 100,000 person-years, and is estimated to be 0.1-0.6% in the hypertensive population
  • diagnosis usually takes place in patients aged 40-50 years
    • however, hereditary variants, such as multiple endocrine neoplasia type 2, Von Hippel-Lindau disease, neurofibromatosis type 1 and the pheochromocytoma-paraganglioma syndrome, can present earlier

Phaeochromocytomas usually secrete a combination of noradrenaline and adrenaline, but some tumours may also secrete dopamine and rarely ACTH causing Cushing's syndrome.

  • rare tumours of (APUD cells)
    • chromaffin cells of the adrenal medulla
    • paraganglion cells of the sympathetic nervous system

  • APUD cells : embryologically derived from the neuroectoderm

  • functionally involved in amine and amine precursor uptake and decarboxylation :APUD

  • occur in a variety of non endocrine (intestines, lungs) and endocrine (adrenals, thyroid, parathyroid) tissues
  • paragangliomas (Extra-adrenal phaeochromocytomas), also called the vascular head and neck tumors, most commonly found at the carotid bifurcation
    • chromaffin tumours arising from aorticosympathetic paraganglia have histologic, biochemical and clinical similarities to phaeochromocytomas and are sometimes referred to as extra-adrenal phaeochromocytomas

May be discovered as an adrenal "incidentaloma"( 5% are pheochromocytomas).

Several genetic syndromes, all of which are transmitted in an autosomal dominant fashion, are known to be associated with an increased risk for pheochromocytoma, including von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), which is associated with mutations in the RET proto-oncogene, and neurofibromatosis type 1 (NF1)

Reference:

  • Harmut PH et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. NEJM 1993;329 (21): 1531-8.
  • Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;20-26;665-75.
  • Guerrero MA, Schreinemakers JM, Vriens MR, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209:727-32.
  • Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.